PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details​​​​​​.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

USO 23009

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC699 in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (AC699-001)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

Eligibility Criteria: 

- Confirmed diagnosis of advanced, unresectable, and/or metastatic breast cancer following disease progression on standard treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies

- Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive (ER+) human epidermal growth factor 2 negative (HER2-) breast cancer

- Must have received at least 2 prior endocrine or at least 1 prior line of endocrine therapy if combined with CDK4/6 inhibitor

- Prior chemotherapy is not required, but up to 3 prior regimens of cytotoxic chemotherapy will be allowed in the locally advanced/ metastatic setting

Available at: